

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-19. (Canceled)

20. (New) A method for preventing a motoneuron disease in a patient in need thereof by increasing the survival and/or growth of motoneurons in said patient comprising administering to said patient a pharmaceutically effective amount of a low molecular weight heparin.

21. (New) The method according to claim 20 wherein the motoneuron disease is amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy or lateral sclerosis.

22. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin has a mean molecular weight of between 1000 and 10000 daltons.

23. (New) The method according to claim 22, wherein the low molecular weight heparin has a mean molecular weight of between 1500 and 6000 daltons.

24. (New) The method according to claim 22, wherein the low molecular weight heparin has a mean molecular weight of between 4000 and 5000 daltons.

25. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin consists of oligosaccharides having a 2-O-sulfo-4-enopyranosuronic acid at one of their ends.

26. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is enoxaparin.

27. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is nadroparin.
28. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is parnaparin.
29. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is reviparin.
30. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is dalteparin.
31. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is tinzaparin.
32. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is danaparoid.
33. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is ardeparin.
34. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is certoparin.
35. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is CY222.
35. (New) The method according to one of claims 20 or 21, wherein the low molecular weight heparin is SR90107/ORG31540.